Puma Biotechnology

Update in progress

PBYI (NasdaqGS)

Puma Biotechnology is a biopharmaceutical company focused on cancer therapies. Its approved product, NERLYNX (neratinib), is an oral treatment for adults with early HER2-overexpressed breast cancer and for advanced disease with capecitabine. It also develops alisertib, an Aurora A kinase inhibitor for several cancers. Sales occur via specialty pharmacies and distributors. It holds Pfizer licenses for neratinib and PB357, plus multiple sub-licenses. Based in Los Angeles and founded in 2010.